In a nutshell, ALL of a manufacturer's advertising/promotional statements must be within the boundaries established by the FDA-cleared/approved intended use and indications. Consequently, if a manufacturer makes claims that the subject device has been tested for, or can be used for, features not directly within the boundaries established by the FDA-cleared/approved intended use and indications, then that generally misbrands the device by way of marketing for uncleared/unapproved indications.
The FDA doesn't generally prohibit clinicians from using their clinical judgment/expertise in the use of medical devices outside of the manufacturer's labeled intended use / indications. Clinicians are allowed to decide whether such "off-label" use is in their patient's best interest.
------------------------------
Kevin Randall, ASQ CQA, RAC (U.S., Europe, Canada)
Principal Consultant
Ridgway, CO
United States
© Copyright 2023 by ComplianceAcuity, Inc. All rights reserved.
------------------------------
Original Message:
Sent: 20-Feb-2023 01:48
From: Anonymous Member
Subject: Indications
This message was posted by a user wishing to remain anonymous
Hi All,
I have a device which is Class II SaMD - FDA and while I write the intended use/indications, the main indications has been studied in a clinical study using primary endpoints and powered, I have also evaluated a feature of the device using a secondary endpoint not powered. I understand the feature studied as a secondary endpoint cannot become part of the indication. But have the following doubts:
- While I market the device can we market saying that the device has also been tested in so and so features (secondary endpoint features)?
- Can the end user use it for the additional feature in clinical practise?
I would greatly appreciate any advice on this regard.
Thanks!